2. Search Result
Search Result
Results for "

atherosclerotic plaque

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

2

Fluorescent Dye

4

Biochemical Assay Reagents

1

Peptides

3

Natural
Products

5

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-117006
    E1231
    1 Publications Verification

    1-{4-[2-(5-Methylfuran-2-yl)quinoline-4-carbonyl]piperazin-1-yl}ethan-1-one

    		 Sirtuin Cardiovascular Disease
    E1231 is an orally active activator of Sirtuin 1 (SIRT1) (EC50=0.83 μM), to modulate cholesterol and lipid metabolism. E1231 interactes with SIRT1 (KD=9.61 μM) and deacetylated liver X receptor-alpha (LXRα), and increases ATP-binding cassette transporter A1 (ABCA1) expression. E1231 also reduces atherosclerotic plaque development in ApoE -/- mice model. E1231 can be used for research in cholesterol and lipid disorder-related diseases .
    E1231
  • HY-113870
    6-NBDG

    		Fluorescent Dye Others
    6-NBDG is a fluorescent glucose analogue, it can be used for fluorescence imaging and monitoring glucose transport and uptake. 6-NBDG can be used as a fluorescent probe for detecting macrophage-rich atherosclerotic plaques .
    6-NBDG
  • HY-107637
    ONO-4817

    		MMP Cardiovascular Disease
    ONO-4817 is a potent inhibitor of matrix metalloproteinase (MMP). Inhibition of matrix metalloproteinases (MMPs) is expected to suppress atherosclerotic neointimal proliferation and thus limits atheromatous plaque progression. ONO-4817 suppresses the development of aortic intimal hyperplasia in experimental hyperlipidemic rabbit .
    ONO-4817
  • HY-173591
    T0080

    		Formyl Peptide Receptor (FPR) Apoptosis Reactive Oxygen Species (ROS) Interleukin Related Cardiovascular Disease
    T0080 is a FPR-1 antagonist. T0080 reduces the cell apoptosis, inhibits ROS production and pro-inflammatory cytokines (TNF-α and IL-1β) from plaque macrophages, which attenuates atherosclerotic progression in ApoE −/− mice .
    T0080
  • HY-159001
    ZCDD083

    		Biochemical Assay Reagents Others
    ZCDD083 can be used as a positron emission tomography (PET) tracer for atherosclerotic plaques imagination, when labeled with 18F isotope .
    ZCDD083
  • HY-E70559
    Prostaglandin D synthase

    		PGE synthase Cardiovascular Disease Cancer
    Prostaglandin D synthase is a biomarker for meningioma cells and coronary artery disease. Lipocalin-type Prostaglandin D synthase (L-PGDS) is present in the atherosclerotic plaque of the human coronary artery and can be detectable in human serum .
    Prostaglandin D synthase
  • HY-172708A
    DSPE-PEG3400-PP1

    		Liposome Neurological Disease
    DSPE-PEG3400-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG3400-PP1 can be used for drug delivery .
    DSPE-PEG3400-PP1
  • HY-172709
    DSPE-PEG5000-PP1

    		Liposome Neurological Disease
    DSPE-PEG5000-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG5000-PP1 can be used for drug delivery .
    DSPE-PEG5000-PP1
  • HY-172708
    DSPE-PEG2000-PP1

    		Liposome Neurological Disease
    DSPE-PEG2000-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG2000-PP1 can be used for drug delivery .
    DSPE-PEG2000-PP1
  • HY-172707
    DSPE-PEG1000-PP1

    		Liposome Neurological Disease
    DSPE-PEG1000-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG1000-PP1 can be used for drug delivery .
    DSPE-PEG1000-PP1
  • HY-146245C
    ODN 1826 sodium
    4 Publications Verification

    CpG 1826 sodium

    		 Toll-like Receptor (TLR) Apoptosis NO Synthase Cardiovascular Disease Inflammation/Immunology Cancer
    ODN 1826 sodium is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. ODN 1826 sodium induces NO and iNOS production and enhances Apoptosis. ODN 1826 sodium enhances immune surveillance. ODN 1826 sodium increases aortic atherosclerotic plaque size. ODN 1826 sodium has antitumor activity against lung cancer, glioma and melanoma .
    ODN 1826 sodium
  • HY-122266
    Orcein

    		Biochemical Assay Reagents Metabolic Disease
    Orcein is an irreversible stain that specifically targets elastic fibers and can interact hydrophobically with the protein components in elastic fibers. Orcein makes elastic fibers in tissues appear purple or purple-red. Orcein can be used for morphological studies of Drosophila polytene chromosomes and for qualitative and quantitative analysis of elastic fibers, collagen fibers and other components in atherosclerotic plaques .
    Orcein
  • HY-146245
    ODN 1826
    4 Publications Verification

    CpG 1826

    		 Toll-like Receptor (TLR) Apoptosis NO Synthase Cardiovascular Disease Inflammation/Immunology Cancer
    ODN 1826 is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. ODN 1826 induces NO and iNOS production and enhances Apoptosis. ODN 1826 enhances immune surveillance. ODN 1826 increases aortic atherosclerotic plaque size. ODN 1826 has antitumor activity against lung cancer, glioma and melanoma .
    ODN 1826
  • HY-135517
    RXP470.1

    RXP-470

    		 MMP Cardiovascular Disease
    RXP470.1 (RXP-470) is a potent, selective MMP-12 inhibitor with a Ki of 0.2 nM against human MMP-12. RXP470.1 is 2 to 4 orders of magnitude less potent against other MMPs. RXP470.1 significantly reduces atherosclerotic plaque cross-sectional area in mouse. RXP470.1 results in less complex plaques with increased smooth muscle cell:macrophage ratio, less macrophage apoptosis, increased cap thickness, smaller necrotic cores, and decreased incidence of calcification .
    RXP470.1
  • HY-173234
    GI-Y2

    		Pyroptosis Cardiovascular Disease
    GI-Y2 is an inhibitor of GSDMD and can inhibit Pyroptosis of macrophages induced by oxidized low-density lipoprotein (ox-LDL). In vivo, GI-Y2 can dose-dependently reduce atherosclerotic plaques in ApoE-/- mice and decrease the lesion size and fibrosis degree of the aortic root. GI-Y2 is expected to be used in the research of pyroptosis and cardiovascular diseases, such as atherosclerosis .
    GI-Y2
  • HY-152221
    PCSK9-IN-10

    		PCSK9 Cardiovascular Disease Metabolic Disease
    PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC50 value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia .
    PCSK9-IN-10
  • HY-10835
    DG-041
    2 Publications Verification

    		 Prostaglandin Receptor Cardiovascular Disease
    DG-041 is a potent, high affinity and selective EP3 receptor antagonist with IC50s of 4.6 nM and 8.1 nM in the binding and FLIPR assay, respectively. DG-041 inhibits PGE2 facilitation of platelet aggregation. DG-041 crosses the blood-brain barrier .
    DG-041
  • HY-113342
    7-Ketocholesterol
    2 Publications Verification

    		 Endogenous Metabolite p38 MAPK Cardiovascular Disease Metabolic Disease
    7-Ketocholesterol is an oxidation product of cholesterol, widely present in atherosclerotic plaques, and has a stronger atherogenic effect than cholesterol. 7-Ketocholesterol can inhibit the rate-limiting enzymes involved in bile acid and cholesterol synthesis, such as cholesterol 7α-hydroxylase and HMG-CoA reductase. 7-Ketocholesterol exhibits pro-inflammatory effects both in vivo and in vitro and can induce cell apoptosis (apoptosis) .
    7-Ketocholesterol
  • HY-W996116
    AZM198

    		Glutathione Peroxidase Cytochrome P450 Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    AZM198 is a selective, orally active, and irreversible MPO inhibitor with an IC50 of 15.0 nM. AZM198 has an IC50 of 19 μM for CYP3A4. AZM198 has favorable lipophilicity, membrane permeability, metabolic stability, safety, and pharmacokinetic properties. AZM198 exhibits activity in improving vascular function, atherosclerotic plaques, pulmonary hypertension, kidney disease, visceral inflammatory fat deposition, ectopic fat deposition, and hepatic fibrosis .
    AZM198
  • HY-113342R
    7-Ketocholesterol (Standard)

    		Endogenous Metabolite p38 MAPK Cardiovascular Disease Metabolic Disease
    7-Ketocholesterol (Standard) is the analytical standard of 7-Ketocholesterol. This product is intended for research and analytical applications. 7-Ketocholesterol is an oxidation product of cholesterol, widely present in atherosclerotic plaques, and has a stronger atherogenic effect than cholesterol. 7-Ketocholesterol can inhibit the rate-limiting enzymes involved in bile acid and cholesterol synthesis, such as cholesterol 7α-hydroxylase and HMG-CoA reductase. 7-Ketocholesterol exhibits pro-inflammatory effects both in vivo and in vitro and can induce cell apoptosis (apoptosis) .
    7-Ketocholesterol (Standard)
  • HY-N2673
    5-Heptadecylresorcinol

    5-n-Heptadecylresorcinol; AR-C17

    		 Sirtuin Cardiovascular Disease Metabolic Disease
    5-Heptadecylresorcinol (AR-C17), a phenolic lipid component, is also an orally active mitochondrial protector. 5-Heptadecylresorcinol improves mitochondrial function via sirtuin3 signaling pathway, thus alleviates endothelial cell damage and apoptosis. 5-Heptadecylresorcinol induces sirtuin3-mediated autophagy. 5-Heptadecylresorcinol reduces the atherosclerotic plaques in the aortic root region of mice heart. 5-Heptadecylresorcinol can be used for research of atherosclerosis prevention and obesity .
    5-Heptadecylresorcinol

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: